A Phase 1 Study of JNJ-86974680, an A2a Receptor Antagonist, Administered as Monotherapy and in Combination With Cetrelimab and Radiotherapy for Advanced Non-small Cell Lung Cancer

Johnson & Johnson Enterprise Innovation Inc.

Summary

The purpose of this study is to determine a safe and tolerable dose(s) of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy.

Eligibility

Age range: 18+ years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: * Individuals with histologically or cytologically confirmed stage IIIB-IV non-small cell lung cancer (NSCLC) * Part 1: NSCLC with a known actionable genetic mutation (for example, epidermal growth factor receptor \[EGFR\], anaplastic lymphoma kinase \[ALK\], c-ros oncogene 1 \[ROS1\], v-raf murine sarcoma viral oncogene homolog B1 \[BRAF\]) must have received all approved targeted therapies and have progressed * Part 2: No targetable mutations (for example, EGFR \[epidermal growth factor receptor\], ALK \[anaplastic lymphoma kinase\], ROS1\[c-ros oncogene 1\], and BRAF \[…

Interventions

Drug
JNJ-86974680
JNJ-86974680 will be administered.
Drug
Cetrelimab
Cetrelimab will be administered.
Radiation
Radiation Therapy
Radiation therapy will be administered.

Locations (15)

City of Hope 1
Newnan, Georgia
Hackensack University Medical Center
Hackensack, New Jersey
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Herbert Irving Comprehensive Cancer Center Columbia University Medical Center
New York, New York
Providence Portland Medical Center
Portland, Oregon
Thomas Jefferson University
Philadelphia, Pennsylvania